Falcon 40B: World’s Top AI Model Rewards Most Creative Use Cases in Call for Proposals with Training Compute Power
7.6.2023 13:21:00 EEST | Business Wire | Press release
Falcon 40B, the world’s top-ranked open-source AI model on the Hugging Face leaderboard for large language models (LLMs), is registering an overwhelming response to a Call for Proposals from scientists, researchers, and SME entrepreneurs keen to deploy the model for innovative use cases.
The response follows back-to-back announcements from the AI model’s creator, Abu Dhabi’s Technology Innovation Institute (TII), offering the most exceptional project ideas access to training compute power as a form of investment.
Compute power enables developers to tackle more complex and resource-intensive use cases with increased efficiency, productivity, and performance. By being able to experiment with the capabilities of Falcon 40B, the best open-source LLM globally, developers can venture into uncharted territories, driving innovation and expanding the possibilities of AI solutions - at speed.
Submissions are being welcomed from all over the world, and across all industries and sectors to find the very best application concepts. Examples of industries include biotech, engineering, enterprise solutions, customer services, finance, and healthcare. In healthcare, for instance, LLM applications could help doctors by analyzing medical literature, patient records, and research findings to provide evidence-based recommendations. This could enable medical practitioners to make informed decisions and improve patient care based on the latest knowledge and insights.
“We strongly encourage scientists, researchers, and aspiring entrepreneurs with bold ideas to submit their proposals for Falcon 40B deployment,” said H.E. Faisal Al Bannai Secretary General of TII’s parent entity, the Advanced Technology Research Council (ATRC). “We’re excited to invest in the most impactful proposals with compute power through VentureOne, ATRC’s commercialization arm, and to potentially partner with the most promising developers.”
“Every proposal that comes our way is subjected to a thorough and meticulous assessment by TII's dedicated AI Cross-Center Unit (AICCU),” said Dr. Ebtesam Almazrouei, Acting Chief Researcher at AICCU. “Our team of over 40 exceptional AI scientists is poised to examine each proposal, seeking developers with exceptional intellect and ingenuity. Our paramount goal is to propel the frontiers of AI advancements, leveraging its full potential to bring about profound societal improvements.”
Interested users should submit a proposal outlining their research objectives, methodology, expected outcomes, and the potential impact of their project. The proposal should highlight how Falcon 40B will be utilized and the specific domain it targets. In addition, applicants should include a timeline and a compute budget estimate, as well as any relevant expertise or previous work that supports their proposal.
If you are interested in entering the Call for Proposals, we invite you to visit FalconLLM.TII.ae.
For more information, visit www.tii.ae
Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230607005466/en/
Contact information
For media inquiries, please contact:
Jennifer Dewan, Senior Director of Communications
jennifer.dewan@tii.ae.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
